Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | NADK | O95544 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674401 | 1.00 | AHCY (0.57) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL6445754 | 1.00 | AHCY (0.57) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL9777803 | 0.88 | AHCY (0.55) | AHCYPRMT5WDR77ADORA1NADK | |
| SCHEMBL24478703 | 0.84 | PRMT5 (0.73) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL22326785 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL21413837 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL800346 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL22326787 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL18520788 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL13173634 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| EP-2248523-A1 | Compounds for use in the treatment of clinical conditions resulting from a deficit of endothelial progenitor cells | Universität zu Köln (DE) | 2010-11-10 | — | — | EP | claimed |
| EP-2204154-A1 | Association of monosaccharides and adenosine and its cosmetic use | L'OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | claimed |
| US-20070232560-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2007-10-04 | — | — | US | claimed |
| EP-1424064-B1 | Use of adenosin or an adenosin analog to smooth out fine lines | OREAL (FR) | 2007-06-06 | — | — | EP | claimed |
| WO-2007042679-A2 | COSMETIC COMPOSITION CONTAINING A NON-PHOSPHATE COMPOUND BASED ON ADENOSINE AND A TIGHTENING POLYMER | L'OREAL (FR) | 2007-04-19 | — | — | WO | claimed |
| US-20060240056-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2006-10-26 | — | — | US | claimed |
| WO-2004056181-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| EP-1424064-A1 | Use of adenosin or an adenosin analog to smooth out fine lines | L'OREAL (FR) | 2004-06-02 | — | — | EP | claimed |
| EP-1087776-A1 | A PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065501-A1 | A PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1999-12-23 | — | — | WO | claimed |
| US-20250381317-A1 | COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF | MODERN MEADOW INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4444253-B1 | COMPOSITION COMPRISING A COMBINATION OF POLYGLYCEROL ESTERS AND A FILLER | OREAL (FR) | 2025-10-08 | — | — | EP | disclosed |
| EP-4598499-A1 | COSMETIC COMPOSITION FOR A MATTE FOUNDATION | L'OREAL (FR) | 2025-08-13 | — | — | EP | disclosed |
| US-4704381-A | ASTHMA | BOEHRINGER MANNHEIM GMBH (DE) | 1987-11-03 | — | — | US | disclosed |
| EP-0152944-A2 | Use of adenosine derivatives as anti-allergic product and pharmaceuticals containing them | Roche Diagnostics GmbH (DE) | 1985-08-28 | — | — | EP | disclosed |
| US-4411881-A | Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines | NEW ENGLAND NUCLEAR CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | AHCY 257/4885PRMT5 715/4885WDR77 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.